HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort StudyThe Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
Corresponding author name: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
Corresponding author e-mail: firstname.lastname@example.org
Citation: Antiviral Therapy 2010; 15:1077-1086
Date published online: 03 November 2010
Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals.
Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy.
Results: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0–3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV-seronegative and HCV-seropositive were 3.3 (3.0–3.7) and 2.7 (2.2–3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8–3.5), 4.2 (3.1–5.2) and 2.8 (1.8–3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62–1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79–1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52–1.15]) and the development of myocardial infarction.
Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.